PharmaEssentia Corporation
6446
Rang in Aktien
#1422
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktienkurs
$37.84
Marktkapitalisierung
$15.65B
Veränderung (1 Tag)
-4.42%
Veränderung (1 Jahr)
149.23%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategorie
Healthcare
EPS für PharmaEssentia Corporation (6446)
EPS zum June 2026 TTM: $0.63
Laut den aktuellen Finanzberichten und dem Aktienkurs von PharmaEssentia Corporation beträgt das aktuelle EPS des Unternehmens (TTM) $0.63. Am Ende des Jahres 2023 betrug das EPS $-0.06 ein Rückgang im Vergleich zu dem EPS von 2022, das $-0.14 betrug.
EPS-Verlauf von PharmaEssentia Corporation von 2010 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.63 | 153.00% |
| 2024 | $0.25 | -534.22% |
| 2023 | $-0.06 | -60.15% |
| 2022 | $-0.14 | -59.50% |
| 2021 | $-0.35 | 37.91% |
| 2020 | $-0.25 | 119.47% |
| 2019 | $-0.12 | -14.95% |
| 2018 | $-0.14 | 15.09% |
| 2017 | $-0.12 | 5.89% |
| 2016 | $-0.11 | -6.67% |
| 2015 | $-0.12 | -4.08% |
| 2014 | $-0.13 | 25.60% |
| 2013 | $-0.10 | 63.82% |
| 2012 | $-0.06 | 25.36% |
| 2011 | $-0.05 | 16.87% |
| 2010 | $-0.04 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -12.05% |
IN
|
